S
Shanghai Hezhou Pharmaceutical
Discovery and development of innovative oncology drugs
About Shanghai Hezhou Pharmaceutical
Shanghai Hezhou Pharmaceutical, also known as Haihe Pharmaceutical, is a biotechnology company focused on the discovery and development of innovative drugs for oncology. The company is advancing a pipeline of drug candidates, with a significant number having reached the clinical trial stage and several receiving Investigational New Drug (IND) approval in the United States. The business model centers on the research, development, and eventual commercialization of these novel cancer therapies on a global scale.
Dr. Ruiping Dong serves as the CEO of the company. Haihe Pharmaceutical has successfully secured significant funding to advance its research and development efforts. In July 2020, the company announced the closing of a ¥1.20 billion Series B financing round. This funding was led by Warburg Pincus and included participation from CMBI, Legend Capital, and CICC Capital, among others. Previous Series A investors such as BioTrack Capital and Atlas Capital also participated in the round, demonstrating continued confidence in the company's pipeline and strategy. The proceeds are intended to accelerate the clinical development and commercialization of its portfolio of oncology drugs.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Aug 2025 | $20M | $80M | Undisclosed | ↗ |
| SEED✓Equity / VC | Oct 2023 | $2.8M | $11M | Eight Roads Ventures | ↗ |
Growth signals
Latest recorded traffic for Shanghai Hezhou Pharmaceutical is 1.3K monthly website visits, up 32.7% over the last three months. Shanghai Hezhou Pharmaceutical's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Shanghai Hezhou Pharmaceutical in its local ecosystem
The Shanghai Hezhou Pharmaceutical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Other known investors1 additional known investor
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Shanghai Hezhou Pharmaceutical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Shanghai Hezhou Pharmaceutical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










